Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine.
Clinical medicine
Ethics
Health humanities
Mental health
Psychedelic medicine
Journal
Culture, medicine and psychiatry
ISSN: 1573-076X
Titre abrégé: Cult Med Psychiatry
Pays: Netherlands
ID NLM: 7707467
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
25
08
2021
pubmed:
4
9
2021
medline:
28
10
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
An international ban on psychedelics initiated by the United Nations' Convention on Psychotropic Substances in 1971 restricted the clinical use of these ancient psychoactive substances. Yet, in an era marked by rising mental health concerns and a growing "Deaths of Despair" epidemic (i.e., excess mortality and morbidity from suicide, drug overdose, and alcoholism), the structured psychedelic use that has long been a part of ritual healing experiences for human societies is slowly regaining credibility in Western medicine for its potential to treat various mental health conditions. We use a historical lens to examine the use of psychedelic therapies over time, translate ancient lessons to contemporary clinical and research practice, and interrogate the practical and ethical questions researchers must grapple with before they can enter mainstream medicine. Given the COVID-19 pandemic and its contributions to the global mental health burden, we also reflect on how psychedelic therapy might serve as a tool for medicine in the aftermath of collective trauma. Ultimately, it is argued that a "psychedelic renaissance" anchored in the lessons of antiquity can potentially help shift healthcare systems-and perhaps the broader society-towards practices that are more humane, attentive to underlying causes of distress, and supportive of human flourishing.
Identifiants
pubmed: 34476719
doi: 10.1007/s11013-021-09749-y
pii: 10.1007/s11013-021-09749-y
pmc: PMC8412860
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
890-903Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
JAMA Netw Open. 2020 Sep 1;3(9):e2016217
pubmed: 32915234
Nat Rev Neurosci. 2013 Aug;14(8):577-85
pubmed: 23756634
J Psychoactive Drugs. 1998 Oct-Dec;30(4):419-26
pubmed: 9924845
PLoS One. 2012;7(2):e30800
pubmed: 22363492
Front Hum Neurosci. 2014 Feb 03;8:20
pubmed: 24550805
J Psychiatr Res. 2021 Jul;139:71-81
pubmed: 34048997
JAMA Intern Med. 2017 Jul 1;177(7):1003-1011
pubmed: 28492829
J Psychopharmacol. 2008 Aug;22(6):603-20
pubmed: 18593734
N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
Cell Rep. 2018 Jun 12;23(11):3170-3182
pubmed: 29898390
Biol Psychiatry. 2015 Oct 15;78(8):572-81
pubmed: 24882567
Br J Psychiatry. 2016 Jun;208(6):507-9
pubmed: 27251688
Brookings Pap Econ Act. 2017 Spring;2017:397-476
pubmed: 29033460
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11207-11212
pubmed: 31061128
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836611
Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15078-83
pubmed: 26575631
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
J Epidemiol Community Health. 2018 May;72(5):359-360
pubmed: 29500311
JAMA Psychiatry. 2021 Feb 1;78(2):121-122
pubmed: 32725172
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
Br J Psychiatry. 2005 Jun;186:457-8
pubmed: 15928353
Sci Rep. 2018 Feb 12;8(1):2861
pubmed: 29434331
BMJ Open. 2020 Nov 9;10(10):e037679
pubmed: 33168586
Pharmacol Biochem Behav. 2020 Jan;188:172837
pubmed: 31830487
Psychoanal Rev. 1997 Apr;84(2):237-55
pubmed: 9211587
J Psychopharmacol. 2014 Nov;28(11):983-92
pubmed: 25213996
J Contextual Behav Sci. 2020 Jan;15:39-45
pubmed: 32864325
Am J Public Health. 2017 Oct;107(10):1541-1547
pubmed: 28817333
JAMA Netw Open. 2021 Jul 1;4(7):e2118134
pubmed: 34297071
Nature. 2017 Jun 13;546(7658):339
pubmed: 28617481
Am J Psychiatry. 2020 May 1;177(5):391-410
pubmed: 32098487
Front Pharmacol. 2021 May 19;12:607529
pubmed: 34093170
PLoS One. 2020 Jun 5;15(6):e0233996
pubmed: 32502181
Exp Clin Psychopharmacol. 2016 Aug;24(4):229-68
pubmed: 27454674
Drug Des Devel Ther. 2019 Aug 27;13:3051-3067
pubmed: 31695324
Am J Public Health. 2017 Oct;107(10):1564-1565
pubmed: 28902554
Am J Geriatr Psychiatry. 2019 Sep;27(9):1028-1030
pubmed: 31047789
NCHS Data Brief. 2018 Nov;(328):1-8
pubmed: 30500322
J Psychopharmacol. 2018 Jul;32(7):725-731
pubmed: 29446697
Sci Adv. 2019 Jun 12;5(6):eaaw1391
pubmed: 31206023
Am J Public Health. 2019 May;109(5):774-780
pubmed: 30969834
Neuropharmacology. 2018 Nov;142:263-269
pubmed: 29288686
Elife. 2018 Oct 25;7:
pubmed: 30355445
J Psychoactive Drugs. 2005 Jun;37(2):203-7
pubmed: 16149334
Int Rev Psychiatry. 2018 Aug;30(4):291-316
pubmed: 30422079
Neurologia. 2015 Jan-Feb;30(1):42-9
pubmed: 21893367
Am J Psychiatry. 1971 Dec;128(6):695-9
pubmed: 5147724
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
Ther Adv Drug Saf. 2020 Jul 23;11:2042098620937899
pubmed: 32782779
Pharmacol Ther. 2004 Feb;101(2):131-81
pubmed: 14761703
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
JAMA Psychiatry. 2021 Jun 16;:
pubmed: 34132765
JAMA. 2019 Nov 26;322(20):1996-2016
pubmed: 31769830
Arch Gen Psychiatry. 2011 Jan;68(1):71-8
pubmed: 20819978
Science. 2010 Jul 30;329(5991):502-4
pubmed: 20671165
Neuroimage. 2020 Sep;218:116980
pubmed: 32454209
Neuropharmacology. 2018 Nov;142:200-218
pubmed: 29284138
Am J Public Health. 2020 Oct;110(10):1538-1544
pubmed: 32816546
Transl Psychiatry. 2021 Apr 8;11(1):209
pubmed: 33833225
J Psychopharmacol. 2018 Jan;32(1):37-48
pubmed: 29039233
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):490-494
pubmed: 33793459